Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aldoxorubicin vs Investigator's Choice in Relapsed/Refractory Soft Tissue Sarcoma
NCT02049905Phase 3Completed
- Sponsor
- ImmunityBio, Inc.
- Start
- Jan 2014
- Primary completion
- May 2017
- Modality
- Prodrugs/Conditional Activator Small Molecules
- Countries
- 13
01
Overview
Phase 3, randomised, open-label trial of aldoxorubicin in soft tissue sarcoma (STS) (2 arms), sponsored by ImmunityBio, Inc. Primary endpoint: Progression-Free Survival at 24 months. Started Jan 2014; status: completed.
02
Drugs
aldoxorubicin
03
Conditions
soft tissue sarcoma (STS)
Beyond the preview
Go deeper on NCT02049905.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02049905.